Advertisement

Report from the First Clinical Trials on Alzheimer’s Disease (CTAD) Asia-China 2018 : Bringing together Global Leaders

  • J. K. ChhetriEmail author
  • P. Chan
  • B. Vellas
  • J. Touchon
  • S. Gauthier
Brief Reports
  • 6 Downloads

Abstract

Population of older adults in Asia, and particularly in China is increasing rapidly. Older population are at increased risk of Alzheimer’s disease (AD) and other dementias. Soon, the Chinese population with AD will represent almost half of the world’s AD population. There is a desperate need of disease modifying therapies to delay or slow the progression of AD, to tackle this emerging healthcare emergency. In this context, the first CTAD Asia-China conference was held in China to bring together Western and Asian leaders in AD. This meeting focused largely on how to develop successful trials in China, utilizing past experiences from the West.

Key words

Dementia Alzheimer’s disease China chinese clinical trials CTAD 

References

  1. 1.
    Tanzi, R. E. The genetics of Alzheimer disease. Cold Spring Harb Perspect 1. Dementia statistics Alzheimer’s Disease International. https://doi.org/www.alz.co.uk/research/statistics. Accessed 1 Oct 2018Google Scholar
  2. 2.
    Cummings J, Fox N. Defining Disease Modifying Therapy for Alzheimer’s Disease. J Prev Alzheimers Dis 2017;4:109–115Google Scholar
  3. 3.
    Feng L, Li J, Yu J-T, et al. Editorial: Prevention of Alzheimer’s Disease in Chinese Populations: Status, Challenges and Directions. J Prev Alzheimers Dis 2018;5:90–94Google Scholar
  4. 4.
    Jia J, Wang F, Wei C, et al. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement 2014;10:1–9Google Scholar
  5. 5.
    Jia J, Wei C, Chen S, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement 2018;14:483–491Google Scholar
  6. 6.
    Jia J, Wei C, Chen S, et al. Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial. Alzheimers Dement (N Y) 2018;4:108–117Google Scholar
  7. 7.
    Cummings J, Fox N, Vellas B, Aisen P, Shan G. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force. J Prev Alzheimers Dis 2018;5:103–109Google Scholar
  8. 8.
    Vellas B, Aisen P, Weiner M, Touchon J. What We Learn from the CTAD (Clinical Trials Alzheimer’s Disease) 2018. J Prev Alzheimers Dis 2018;5:214–215Google Scholar

Copyright information

© Serdi Edition 2019

Authors and Affiliations

  • J. K. Chhetri
    • 1
    • 2
    • 3
    Email author
  • P. Chan
    • 1
    • 2
  • B. Vellas
    • 3
  • J. Touchon
    • 4
  • S. Gauthier
    • 5
  1. 1.Department of Neurobiology, Geriatrics and NeurologyXuanwu Hospital of Capital Medical UniversityBeijingChina
  2. 2.China National Clinical Research Center for Geriatric DisordersXuanwu Hospital of Capital Medical UniversityBeijingChina
  3. 3.Department of Geriatrics, Gerontopole, World Health Organization (WHO) Collaborating Center for Frailty, Clinical Research and Geriatric trainingUniversity of ToulouseToulouseFrance
  4. 4.INSERM U 1061University Hospital of MontpellierMontepellierFrance
  5. 5.McGill Center for Studies in AgingMontrealCanada

Personalised recommendations